Resigratinib

1 1

Selleck Chemicals

E1814-5MG

€193,00 EUR
€193,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
View full details

Resigratinib is an inhibitor of FGFR used in studies of MAPK / ERK Signaling. It is especially relevant in cancer and cell signaling models, where defined compound exposure can be linked to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling.

By inhibiting FGFR, Resigratinib can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer and cell signaling models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

  • Target-focused assays involving FGFR
  • Pathway perturbation studies connected to MAPK / ERK Signaling
  • Concentration-response inhibition and target-dependence studies
  • Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Resigratinib is appropriate when a defined chemical perturbant is needed to connect FGFR with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer and cell signaling models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.

Targets:
FGFR
Target Class:
Kinase
Pathways:
MAPK / ERK Signaling
Research Area:
Cancer • Cell Signaling
CAS No.:
2750709-91-0
Molecular Weight:
523.54
Formula:
C₂₆H₂₇F₂N₇O₃
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.